London, United Kingdom, June 17, 2026, Chainwire
The landmark transaction brings the company’s real operating shares into the Solana-based token capital formation
First Block deploys the next generation digital securities architecture for real-world operating businesses
Onpharma’s dental medical device technology provides recurring revenue, high gross margins, and significant market opportunity for token capital appreciation.
This offer is available to invest in sto.onpharma.com
First Block Companya digital securities and token infrastructure company, along with… On Pharma Company (Delaware) based in the United Kingdom Cryto Capital LLPToday announces the launch of what is believed to be the first Solana-based security token offering (“STO”) for an established US operator, marking a structural turning point in the modernization of global private markets.
Coding framework
STO deploys the Solana blockchain infrastructure that combines atomic settlement technology, programmable proprietary architecture, and digital distribution capabilities, and is regulated under existing US securities law. While traditional private markets have suffered from fragmented, multi-intermediary operations, the tokenized framework enables cross-border issuance, settlement and distribution to qualified investors quickly, transparently and at low cost. Secondary on-chain transactions occur via compliant wallets subject to KYC controls, providing near-instant settlement, secondary trading liquidity, and international access under Regulation S and other applicable frameworks.
STO structure
A security token offering represents and transfers ownership rights in a company’s common stock via blockchain-based digital tokens rather than traditional share registries. Designed as an offshore version of Regulation S for non-U.S. investors, the Onpharma STO combines the legal certainty of an exempt securities offering with the operational efficiency of Solana’s infrastructure, settlement and distribution at a speed and cost that traditional private markets cannot match.
Onpharma: the investment case
Onpharma occupies a unique position in the global dental technology space. Its Onset EZ local anesthetic product is already used to stock millions of dental injections annually, addressing the slow, inconvenient and unreliable performance of dental local anesthetics that has remained largely unsolved for decades. The Onset EZ Pen requires no assembly or specialized training, as it integrates directly into your existing workflow to improve the patient experience.
Onpharma is at a post-validation and pre-scale inflection point: infrastructure, supply chain, regulatory compliance and initial commercialization are complete, while the growth phase has begun. Septodont’s entry into the market in February 2025 validated anesthesia buffering as an emerging standard of care, reducing category risk and increasing awareness. The Onset EZ Disposable Pen delivers operational leverage through scalable direct marketing, customer conversion, and repeat consumer revenue. The global dental sedation relief market is valued at US$2 billion and is expected to reach US$2.65 billion by 2030. The capital raised will expand field sales and expand direct selling via the company’s recently deployed AI marketing tools.
Infrastructure
First Block’s digital securities architecture supports the transaction from issuance and compliance to Solana-based settlement and distribution, compressing traditional private placement infrastructure, fragmented custody arrangements, manual processing, and multi-broker chains, into a single programmable, blockchain-enabled system designed for the scale, speed, and portfolio-level accessibility that international investors increasingly need. Crito Capital LLP, an FCA-certified investment banking and advisory platform focused on institutional capital formation, is providing structuring and advisory for the offering.
“This is bigger than traditional financing,” said Daniel P. Cannon, CEO of First Block. “We believe this transaction represents the beginning of the convergence of capital markets and Solana-based securities infrastructure. The STO itself is the story, but it starts with a real operating company, a real product, and exceptional potential for revenue growth.”
“Onpharma has spent years building a real business around a simple clinical goal: making local anesthetics better for dentists and patients,” said Matt Stepovich, CEO of Onpharma. “This offering allows us to offer a proven, income-generating medical device platform to a broader base of qualified international investors via a structure that reflects how capital markets evolve. Combining the power of Onpharma’s real-world commercial traction with First Block’s Solana-based securities infrastructure is an important step in making growth capital formation more efficient, accessible and transparent.”
Additional details regarding the offering structure and participation frameworks are available on the landing page for the STO offering linked here – sto.onpharma.com
About First Block Company
First Block Company is a digital securities and infrastructure company focused on consensus tokenization, STO, real-world asset digitization, and Solana-based settlement architecture for global markets.
About On Pharma Company
On Pharma Company He develops dental techniques focused on improving local anesthesia in dentistry. The Onset EZ Pen buffering platform improves anesthesia reliability, speeds up start time, and makes dental anesthetic injections more comfortable.
About Cryto Capital LLP
Cryto Capital LLP is a UK-based advisory and investment banking firm licensed and regulated in the UK, focusing on institutional capital markets, strategic consulting and emerging financial technology.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding Onpharma Corporation’s (the “Company”)’s business strategy, expected growth, market opportunities, product development, commercialization efforts, expected revenues, financing plans, digital asset initiatives, tokenization initiatives, regulatory matters, and future operations. These statements are based on current expectations, estimates, assumptions and projections that involve significant risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by the forward-looking statements due to a variety of factors, including, but not limited to, market conditions, regulatory developments, availability of financing, competition, technological developments, product adoption, operational implementation and other risks and uncertainties. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.
This press release is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offering of securities referred to herein will be made only in accordance with the definitive offering documents and in compliance with applicable securities laws and regulations. The offering referred to herein is intended only for non-U.S. persons in offshore transactions pursuant to Regulation S under the Securities Act and is not directed to or intended for U.S. persons or investors resident in the United States.
communication
Mr.
Richard Morgan Evans
Communications wise
rmorganevans@sapiencecomms.co.uk
